Copyright ©The Author(s) 2021.
World J Clin Oncol. Jul 24, 2021; 12(7): 565-580
Published online Jul 24, 2021. doi: 10.5306/wjco.v12.i7.565
Table 1 Ongoing trials including patients carrying gastro-intestinal cancer with BRCA1m and/or BRCA2m and solid tumours with BRCA1m and/or BRCA2m

Study title
Trial description
NCT03337087Liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib in treating patients with metastatic pancreatic, colorectal, gastroesophageal, or biliary cancerPhase IRecruitingExperimental: nal-IRI, leucovorin, fluorouracil, rucaparib
NCT02286687Talazoparib in treating patients with recurrent, refractory, advanced, or metastatic cancers and alterations in the BRCA genesPhase IIaRecruitingExperimental: Talazoparib
NCT03428802Pembrolizumab in treating participants with metastatic, recurrent or locally advanced cancer and genomic instabilityPhase IIaRecruitingExperimental: Pembrolizumab
NCT04503265A trial of AMXI-5001 for treatment in patients with advanced malignanciesPhase I-IIaRecruitingExperimental: AMXI-5001 (oral PARP and microtubule polymerization inhibitor)
NCT04171700A study to evaluate rucaparib in patients with solid tumors and with deleterious mutations in HRR genes (LODESTAR)Phase IIaRecruitingExperimental: Rucaparib
NCT03415659Phase I clinical study of HWH340 tablet in patients with advanced solid tumorsPhase IRecruitingExperimental: HWH340 monotherapy
NCT02723864Veliparib (ABT-888), an Oral PARP inhibitor, and VX-970, an ATR inhibitor, in combination with cisplatin in people with refractory solid tumorsPhase IActive, not recruitingExperimental: VX-970 at Days 2 and 9 of each 21-d cycle; veliparib twice a day (BID) days 1-3 and 8-10 of each cycle; cisplatin at day 1 (and day 8 from DL3 onwards) of each cycle
NCT00516373A study to assess the safety and pharmacokinetics of an inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)Phase IActive, not recruitingExperimental: KU-0059436 (oral PARP inhibitor)
NCT04439227Testing AZD1775 as a potential targeted treatment in cancers with BRCA genetic changes (MATCH-Subprotocol Z1I)Phase IIActive, not recruitingExperimental: Adavosertib
NCT03565991Javelin BRCA/ATM: Avelumab plus talazoparib in patients with BRCA or ATM mutant solid tumorsPhase IIActive, not recruitingExperimental: Combination of avelumab and talazoparib
NCT01482715A study of oral rucaparib in patients with a solid tumor (Phase I) or with gBRCA mutation ovarian cancer (Phase II)Phase I-IIaCompletedExperimental: Rucaparib
NCT01989546Pilot trial of BMN 673, an oral PARP Inhibitor, in patients with advanced solid tumors and deleterious BRCA mutationsPhase I-IIaCompletedExperimental: Talazoparib (BMN 673)
NCT01286987Study of Talazoparib, a PARP Inhibitor, in patients with advanced or recurrent solid tumorsPhase ICompletedExperimental: Talazoparib
NCT03767075A modular multi-basket trial to improve personalized medicine in cancer patients (BoB)Phase IIRecruitingExperimental: Atezolizumab